Dr. Lina Freage-Kahn is the Chief Scientific Officer at Frezent. She obtained a PhD in Organic Chemistry & Biochemistry at The Hebrew University of Jerusalem, and completed a postdoctoral fellowship in Cell Biology & Immunotherapy at the Research Foundation, CUNY. Her research expertise lies in immuno-oncology and the biochemistry of the cancer microenvironment, focusing on developing innovative immunotherapies and targeted cancer treatments. Prior to joining Frezent as a CSO, Dr. Freage-Khan worked on synthesizing chemically modified DNA aptamers to enhance immune system targeting within the tumour microenvironment. Her collaborative efforts across multidisciplinary teams contributed to more effective therapeutic strategies, specifically in modulating the immune response in cancer.